A novel immune therapy has driven an otherwise incurable form of T-cell leukaemia into remission in a small group of patients, offering new hope.

Scientists discovered that certain cancer cells use a low-level activation of a DNA-dismantling enzyme—normally seen in cell ...

Treatment with an immune and cancer cell-targeting antibody therapy eradicates residual traces of the blood cell cancer multiple myeloma, according to interim results from a clinical trial conducted ...

A small group of patients with an otherwise incurable form of T‑cell leukemia have seen their cancer driven into remission by ...

The FDA on Tuesday approved etuvetidigene autotemcel (Waskyra) as the first cell-based gene therapy for patients 6 months and ...

An experimental monoclonal antibody called ianalumab had promising results for more than half of patients with primary immune thrombocytopenia enrolled in a phase 3 trial, according to data published ...

Researchers from the Keck School of Medicine of USC have developed a new type of chimeric antigen receptor (CAR) T cell that ...

A breakthrough therapy is driving aggressive leukaemia into remission. Here’s what the headlines don’t tell you about life ...

The FDA has issued its stamp of approval to a new, cell-based option to treat Wiskott-Aldrich syndrome (WAS), marking the ...

Is your favorite celebrity getting NAD+ therapy — and should you be too? The answer: maybe, but more research is needed to know for sure. NAD+, or nicotinamide adenine ...

Backed by Italy-based Fondazione Telethon ETS, Waskyra, for Wiskott-Aldrich syndrome, is the first gene therapy from a ...

Scientists at UCL and GOSH have used groundbreaking base-edited CAR‑T cell therapy — BE‑CAR7 — to treat aggressive T‑cell ...